ALX Oncology Holdings Inc. (ALXO) Dividend History

ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies that target immune evasion mechanisms in cancer. The company’s lead program aims to improve outcomes for patients by restoring the immune system’s ability to fight tumors. Headquartered in the United States, ALX Oncology is dedicated to advancing research and development in immuno-oncology.

323 Allerton Avenue, South San Francisco, CA, 94080
Phone: 650-466-7125
Website: https://www.alxoncology.com

Dividend History

ALX Oncology Holdings Inc. currently does not pay dividends

Company News

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology announced it will host a webcast event on May 20, 2025, to provide an update on its investigational antibody-drug conjugate ALX2004, which is designed to treat EGFR-expressing tumors.

GlobeNewswire Inc.
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.

Benzinga

Featured Companies: CRDF EXEL ONCY VSTM
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology announced that the updated results from its Phase 2 ASPEN-06 clinical trial of evorpacept in combination with trastuzumab, CYRAMZA, and paclitaxel for the treatment of HER2-positive gastric/gastroesophageal junction cancer will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium.

GlobeNewswire Inc.
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

ALX Oncology announced that results from a Phase 1b/2 trial evaluating evorpacept in combination with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

GlobeNewswire Inc.
Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The breast cancer pipeline is robust with over 100 active players working on 120+ pipeline drugs. Key companies like Ambrx, Merus, and Regeneron are evaluating promising therapies to improve the treatment landscape.

GlobeNewswire Inc.

Featured Companies: ABBV JAZZ MRUS REGN

Dividend data last updated 06/07/2025 14:57:41 UTC